# Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

> **NCT01189266** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 79 (actual)

## Conditions studied

- Anaplastic Astrocytoma
- Anaplastic Oligoastrocytoma
- Diffuse Intrinsic Pontine Glioma
- Gliosarcoma

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01189266
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-09
- **Primary completion:** 2017-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189266, "Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01189266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*